The place of risperidone in situ microparticles (ISM®) among long-acting injectable antipsychotics in schizophrenia treatment

Key Points

• Risperidone in situ microparticles can enhance adherence in patients with schizophrenia, improving treatment outcomes.
• Long-acting injectable antipsychotics are crucial for managing schizophrenia, yet unmet needs for rapid symptom control persist.
• Assessment of risperidone in situ microparticles indicates potential for better efficacy-tolerability balance than traditional therapies.
• Findings suggest that further research is needed to evaluate the long-term impact of this treatment on patient lives.